Advertisement

Chorionic villus sampling and the risk of adverse outcome in patients undergoing multifetal pregnancy reduction

      Objective

      The objective of the study was to determine whether patients undergoing chorionic villus sampling (CVS) prior to MPR are at increased risk for adverse outcome compared to those who did not.

      Study Design

      We retrospectively identified multifetal pregnancy reduction (MPR) patients from an established database. Maternal demographic data were collected. Outcomes including complete pregnancy loss prior to 24 weeks' gestation, gestational age at delivery, and birthweight were analyzed.

      Results

      There was no significant difference in pregnancy loss between the 2 groups (CVS [4%] vs no CVS [7%], P = .098). When stratified by finishing number, there was a significantly lower loss rate in the singleton CVS group (2% vs 9%, P = .025) and no significant difference in reduced twins. There was no significant difference in the average gestational age of delivery or birthweight.

      Conclusion

      CVS prior to MPR does not increase the risk of pregnancy loss. Our data suggest that CVS prior to singleton reduction may decrease the risk of adverse outcome.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Martin J.A.
        • Hamilton B.E.
        • Sutton P.D.
        • et al.
        Births: Final data for 2004.
        Natl Vital Stat Rep. 2006; 55: 1-101
        • American College of Obstetricians and Gynecologists
        Screening for fetal chromosomal abnormalities.
        The College, Washington (DC)2007
        • Berkowitz R.L.
        • Lynch L.
        • Chitkara U.
        • et al.
        Selective reduction of multifetal pregnancies in the first trimester.
        N Engl J Med. 1988; 318: 1043-1047
        • Brambati B.
        • Tului L.
        • Baldi M.
        • Guercilena S.
        Genetic analysis prior to selective fetal reduction in multiple pregnancy: Technical aspects and clinical outcome.
        Hum Reprod. 1995; 10: 818-825
        • Eddleman K.A.
        • Stone J.L.
        • Lynch L.
        • Berkowitz R.L.
        Chorionic villus sampling before multifetal pregnancy reduction.
        Am J Obstet Gynecol. 2000; 183: 1078-1081
        • Brambati B.
        • Tului L.
        • Guercilena S.
        • Alberti E.
        Outcomes of first-trimester chorionic villus sampling for genetic investigation in multiple pregnancy.
        Ultrasound Obstet Gynecol. 2001; 17: 209-216
        • Berkowitz R.L.
        • Lynch L.
        • Lapinski R.
        • Bergh P.
        First trimester transabdominal multifetal pregnancy reduction: A report of two-hundred completed cases.
        Am J Obstet Gynecol. 1993; 169: 17-27
        • American College of Obstetricians and Gynecologists
        Invasive prenatal testing for aneuploidy; ACOG practice bulletin no. 88.
        The College, Washington (DC)2007
        • Brambati B.
        • Tului L.
        • Camurri L.
        • Guercilena S.
        First trimester fetal reduction to a singleton infant or twins: Outcome in relation to the final number and karyotyping before reduction by transabdominal chorionic villus sampling.
        Am J Obstet Gynecol. 2004; 191: 2035-2040
        • Stone J.
        • Belogolovkin V.
        • Matho A.
        • Berkowitz R.L.
        • Moshier E.
        • Eddleman K.
        Evolving trends in 2000 cases of multifetal pregnancy reduction: A single-center experience.
        Am J Obstet Gynecol. 2007; 197: 394.e1-394.e4
        • Wald N.J.
        • Rish S.
        • Hackshaw A.K.
        Combining nuchal translucency and serum markers in prenatal screening for Down syndrome in twin pregnancies.
        Prenat Diagn. 2003; 23: 588-592
        • Lynch L.
        • Berkowitz R.L.
        Maternal serum alpha-fetoprotein and coagulation profiles multifetal pregnancy reduction.
        Am J Obstet Gyencol. 1993; 169: 987-990